Date: 2014-05-20
Type of information:
phase: 1
Announcement: initiation of the trial
Company: Isis Pharmaceuticals (USA)
Product: ISIS-PKK Rx
Action
mechanism: ISIS-PKKRx¬ is an antisense drug designed to reduce the production of PKK in the liver and therefore alter the course of disease in patients who have severe HAE attacks. It targets the prekallikren (PKK), a protein produced in the liver that plays an important role in the activation of inflammatory mediators associated with acute attacks of HAE. This is a well-validated pathway and one that is easily accessible using our antisense technology.
Disease: hereditary angioedemia (HAE)
Therapeutic area: Rare diseases
Country:
Trial details:
Latest
news: * On May 20, 2014, Isis Pharmaceuticals announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE). Isis plans to complete the Phase 1 study of ISIS-PKKRx and initiate a Phase 2 study in patients with HAE.
